Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV50 and MEV90 of 0.2% ropivacaine for ultrasound-guided median nerve block in pediatric trigger finger surgery
ChiCTR2100045225Phase 4Recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ropivacaine in trigger finger, sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: EV50 (50% minimum effective volume) and MEV90 (90% minimum effective volume). Started Apr 2021; status: recruiting.
02
Drugs
ropivacaine
03
Conditions
trigger finger
Beyond the preview
Go deeper on ChiCTR2100045225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045225.